Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations...
Clinical Trial
Xenon MRI Featured Prominently at ATS 2025 Across Broad Clinical Spectrum
30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRIDURHAM, NC and LONDON, May...
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
- First ASXL1 Pediatric Acute Myeloid Leukemia (AML) Patient Dosed at MD Anderson Cancer Center: Program Supported by Rare Pediatric...
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic...
CytoDyn Releases ESMO Breast Cancer Meeting Poster
VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing...
Adial Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GLEN ALLEN, Va., May 15, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage...
Excision BioTherapeutics Announces Publication Highlighting EBT-107 for the Treatment of Chronic Hepatitis B in bioRxiv
Treatment with EBT-107 led to a rapid reduction in clinical biomarkers and suppression of random HBV DNA integration with minimal...
NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates
Completed last subject, last visit in the chronic cohort, data readout targeted for early June 2025Vancouver, British Columbia--(Newsfile Corp. -...
Conference Forum Announces the Partnerships with Sites Summit to Improve Patient Enrollment
The Conference Forum announces the Partnerships with Sites Summit to address the unmet need of patient enrollment at clinical sites...
Sanford Health and Cedar Partner to Bring Cutting-Edge Financial Solutions to Rural Care
The nation's largest rural Epic health system selects Cedar to enhance the patient financial experience in America's heartland NEW YORK, May...
REACH Trial Evaluating First-Line Treatment of Refractory Chronic Cough Completes Enrollment
Top-line data anticipated in early Q3 2025. BOSTON--(BUSINESS WIRE)--Sensory Cloud Inc., a health technology company pioneering treatments for respiratory illnesses...
REACH Trial Evaluating First-Line Treatment of Refractory Chronic Cough Completes Enrollment
Top-line data anticipated in early Q3 2025. BOSTON--(BUSINESS WIRE)--Sensory Cloud Inc., a health technology company pioneering treatments for respiratory illnesses...
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14,...
Cannabix Enters Sales Distribution Agreement with Australian Distributor for BreathLogix Autonomous Alcohol Breathalyzer
Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settingsVANCOUVER, British...
Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results
- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - -...
Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories
Clear Regulatory Path to Clinical Trials for Intranasal PTSD Therapy Targeting Multi-Billion-Dollar MarketSARASOTA, FL, May 14, 2025 (GLOBE NEWSWIRE) --...
Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway
Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules...
UPDATE — Abeona Therapeutics® and Lurie Children’s Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
- ZEVASKYN, the first and only cell-based gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), now commercially available...
IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights
Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still...
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2...